New eczema pill shows promise in early safety trial
NCT ID NCT06345404
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This early-stage study tested an experimental pill called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and tolerable compared to a placebo. Researchers also looked at whether it could reduce eczema severity and skin symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
Camp Hill, Pennsylvania, 17011, United States
-
Clinical Site 10
Castle Rock, Colorado, 80109, United States
-
Clinical Site 11
Brooklyn, New York, 11203, United States
-
Clinical Site 12
New York, New York, 10075, United States
-
Clinical Site 13
Pomona, California, 91767, United States
-
Clinical Site 14
San Antonio, Texas, 78213, United States
-
Clinical Site 15
Mayfield Heights, Ohio, 44124, United States
-
Clinical Site 16
New York, New York, 10023, United States
-
Clinical Site 2
Fremont, California, 94538, United States
-
Clinical Site 3
North Little Rock, Arkansas, 72117, United States
-
Clinical Site 4
Frisco, Texas, 75034, United States
-
Clinical Site 5
Birmingham, Alabama, 35244, United States
-
Clinical Site 6
Tampa, Florida, 33615, United States
-
Clinical Site 7
Palo Alto, California, 94063, United States
-
Clinical Site 8
Philadelphia, Pennsylvania, 19103, United States
-
Clinical Site 9
Tucson, Arizona, 85704, United States
Conditions
Explore the condition pages connected to this study.